Drugs / K201
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00863005 | — | atopic eczema | Moberg Pharma AB | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01259622 | Feb → Oct 2011 | atrial fibrillation | Sequel Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT01067833 | Apr 2010 → Oct 2011 | atrial fibrillation | Sequel Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00626652 | Mar 2008 → Dec 2009 | atrial fibrillation | Sequel Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00626652 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT00626652 ↗ |